Pulmonary fibrosis is scarring and stiffening of the lung tissue that makes breathing progressively harder. As healthy, elastic lung tissue is replaced by thick scar tissue, the lungs can't expand or transfer oxygen normally. When the scarring is caused by inhaled asbestos fibers, it's called asbestosis, a specific type of pulmonary fibrosis.
Origin
From the Latin pulmo ("lung") and fibrosis ("formation of fibrous tissue"). The link between asbestos dust and lung scarring was documented in the 1920s and 1930s, giving rise to the term asbestosis.
Significance in Asbestos Context
For asbestos patients, pulmonary fibrosis is the underlying process behind asbestosis, a serious non-cancerous disease. It shows up on imaging as scarring, often in the lower lungs, and on breathing tests as reduced lung capacity. Doctors distinguish asbestos-caused fibrosis from other causes, such as idiopathic pulmonary fibrosis, using exposure history, the pattern of scarring, and signs like pleural plaques. A fibrosis diagnosis can qualify a person for compensation and also signals a higher lifetime risk of lung cancer and mesothelioma, so ongoing monitoring matters.
Example Sentence
His pulmonary fibrosis, confirmed as asbestosis by HRCT and a 30-year insulation work history, explained the shortness of breath he'd blamed on getting older.
Related Terms
Asbestosis, Pleural Plaques, Restrictive Lung Disease, HRCT, Pulmonary Function Test, Idiopathic Pulmonary Fibrosis
Notes
- Ask whether your fibrosis pattern and history point to asbestosis versus another cause; the distinction matters medically and legally.
- Request copies of HRCT scans and pulmonary function tests, which document the disease and its severity.
- Even with a benign fibrosis diagnosis, ask about surveillance for lung cancer and mesothelioma given the shared exposure.
In the research library
393 studies in our medical research library mention Pulmonary Fibrosis in the title or abstract. Among the most cited:
- Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trialJ. Behr, A. Prasse, M. Kreuter, et al, 2021 · The Lancet. Respiratory Medicine · cited 419 times
- A spatially restricted fibrotic niche in pulmonary fibrosis is sustained by M-CSF/M-CSFR signalling in monocyte-derived alveolar macrophagesN. Joshi, S. Watanabe, R. Verma, et al, 2020 · The European Respiratory Journal · cited 293 times
- The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosisB.D. Bringardner, C.P. Baran, T.D. Eubank, et al, 2008 · Antioxidants & Redox Signaling · cited 259 times
- Bronchoalveolar lavage in pulmonary fibrosis: comparison of cells obtained with lung biopsy and clinical featuresP.L. Haslam, C.W. Turton, B. Heard, et al, 1980 · Thorax · cited 246 times
- The epithelium in idiopathic pulmonary fibrosis: breaking the barrierA. Camelo, R. Dunmore, M.A. Sleeman, et al, 2014 · Frontiers in Pharmacology · cited 200 times
The journals that publish most on it: American Journal of Industrial Medicine (18), The American Review of Respiratory Disease (15), British Journal of Industrial Medicine (14).
Category: Diseases & Conditions · All Lexicon terms A–Z
This page is provided for general informational purposes and does not constitute legal advice. Every asbestos case turns on its own facts, exposure history, diagnosis, deadlines, available evidence, and applicable law. Reviewing this page does not create an attorney-client relationship. For advice about your specific situation, call 833-4-ASBESTOS for a free case review.